[go: up one dir, main page]

CY1108927T1 - Αναστολεις μιτωτικης κινεσινης - Google Patents

Αναστολεις μιτωτικης κινεσινης

Info

Publication number
CY1108927T1
CY1108927T1 CY20091100367T CY091100367T CY1108927T1 CY 1108927 T1 CY1108927 T1 CY 1108927T1 CY 20091100367 T CY20091100367 T CY 20091100367T CY 091100367 T CY091100367 T CY 091100367T CY 1108927 T1 CY1108927 T1 CY 1108927T1
Authority
CY
Cyprus
Prior art keywords
suspensions
mitotic kinesin
compounds
ksp kinesin
treating
Prior art date
Application number
CY20091100367T
Other languages
English (en)
Inventor
Paul J Coleman
Christopher D Cox
Robert M Garbaccio
George D Hartman
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of CY1108927T1 publication Critical patent/CY1108927T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά διϋδροπυρρολοενώσεις του Τύπου (I) που είναι χρήσιμες για την θεραπεία κυτταρικών πολλαπλασιαστικών ασθενειών, για την θεραπεία διαταραχών που σχετίζονται με δραστικότητα KSP κινεσίνης, και για την αναστολή KSP κινεσίνης. Η εφεύρεση επίσης αφορά συνθέσεις που περιλαμβάνουν αυτές τις ενώσεις, και μεθόδους χρήσης αυτών στην θεραπεία καρκίνου σε θηλαστικά.
CY20091100367T 2003-08-15 2009-03-30 Αναστολεις μιτωτικης κινεσινης CY1108927T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49563703P 2003-08-15 2003-08-15
US56358004P 2004-04-19 2004-04-19
EP04780791A EP1664026B1 (en) 2003-08-15 2004-08-11 Mitotic kinesin inhibitors

Publications (1)

Publication Number Publication Date
CY1108927T1 true CY1108927T1 (el) 2014-07-02

Family

ID=34221386

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100367T CY1108927T1 (el) 2003-08-15 2009-03-30 Αναστολεις μιτωτικης κινεσινης

Country Status (15)

Country Link
US (2) US7465746B2 (el)
EP (1) EP1664026B1 (el)
JP (1) JP4773961B2 (el)
AT (1) ATE421512T1 (el)
AU (1) AU2004266232B2 (el)
CA (1) CA2534065A1 (el)
CY (1) CY1108927T1 (el)
DE (1) DE602004019229D1 (el)
DK (1) DK1664026T3 (el)
ES (1) ES2319429T3 (el)
HR (1) HRP20090195T1 (el)
PL (1) PL1664026T3 (el)
PT (1) PT1664026E (el)
SI (1) SI1664026T1 (el)
WO (1) WO2005019206A1 (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1515724B1 (en) * 2002-06-14 2009-10-21 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003106417A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2004247023A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
CN1835746A (zh) 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
PT1664026E (pt) * 2003-08-15 2009-04-23 Merck & Co Inc Inibidores de cinesina mitótica
AU2004266629B2 (en) 2003-08-15 2009-11-26 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
JP2007533762A (ja) * 2004-04-19 2007-11-22 メルク　エンド　カムパニー　インコーポレーテッド ２，２−二置換ピロールの調製方法
US7718687B2 (en) 2004-07-01 2010-05-18 Merck Sharp & Dohme Corp., Prodrugs of mitotic kinesin inhibitors
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
EP1861097A4 (en) * 2005-03-16 2010-01-13 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
CL2008003063A1 (es) 2007-10-19 2010-01-04 Schering Corp Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.
NZ589825A (en) 2008-06-19 2012-11-30 Takeda Pharmaceutical Heterocyclic compound and use thereof
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
PH12013501758A1 (en) * 2011-02-25 2013-10-14 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CN104370939B (zh) * 2014-10-14 2016-10-26 上海交通大学 一种手性二氢吡咯类化合物的制备方法
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
MX2019012233A (es) 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
CN112805006B (zh) 2018-08-07 2024-09-24 默沙东有限责任公司 Prmt5抑制剂
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
KR20240135076A (ko) 2021-08-10 2024-09-10 애브비 인코포레이티드 니코틴아미드 ripk1 억제제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3142699A (en) * 1958-04-24 1964-07-28 Bayer Ag Urethane compounds and process therefor
US3635982A (en) * 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
US4477389A (en) * 1982-10-25 1984-10-16 The United States Of America As Represented By The Secretary Of Agriculture Polyhalogenated phenyl isocyanate synthesis with excess phosgene and either triethylamine or tetramethylurea
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
EP0934265B1 (en) 1996-08-16 2003-01-02 Bristol-Myers Squibb Pharma Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6440686B1 (en) * 2000-06-15 2002-08-27 Cytokinetics, Inc. Methods for screening and therapeutic applications of kinesin modulators
CA2467916A1 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2003177052A (ja) * 2001-12-13 2003-06-27 Takata Corp シート重量計測装置
DE60329990D1 (de) * 2002-03-08 2009-12-24 Merck & Co Inc Mitotische kinesin-hemmer
EP1517904A4 (en) * 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
AU2003231799A1 (en) * 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1515724B1 (en) * 2002-06-14 2009-10-21 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003106417A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
US6835899B2 (en) * 2002-08-21 2004-12-28 Trw Inc. Load sensing assembly for a vehicle seat
US7235580B2 (en) * 2002-10-18 2007-06-26 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1636182A4 (en) * 2003-06-12 2008-09-03 Merck & Co Inc PRODRUGS OF INHIBITORS FROM MITOTIC KINESINE
WO2004112699A2 (en) * 2003-06-12 2004-12-29 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2007502279A (ja) * 2003-08-13 2007-02-08 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
AR045342A1 (es) * 2003-08-15 2005-10-26 Merck & Co Inc Inhibidores de quinesina mitotica
PT1664026E (pt) * 2003-08-15 2009-04-23 Merck & Co Inc Inibidores de cinesina mitótica
CN1835746A (zh) * 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
US7294640B2 (en) * 2004-02-06 2007-11-13 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
SI1664026T1 (sl) 2009-04-30
JP4773961B2 (ja) 2011-09-14
US20060234984A1 (en) 2006-10-19
PT1664026E (pt) 2009-04-23
ATE421512T1 (de) 2009-02-15
PL1664026T3 (pl) 2009-06-30
CA2534065A1 (en) 2005-03-03
EP1664026A1 (en) 2006-06-07
EP1664026B1 (en) 2009-01-21
WO2005019206A1 (en) 2005-03-03
HRP20090195T1 (en) 2009-05-31
JP2007502774A (ja) 2007-02-15
US7465746B2 (en) 2008-12-16
ES2319429T3 (es) 2009-05-07
DE602004019229D1 (de) 2009-03-12
AU2004266232B2 (en) 2008-07-03
DK1664026T3 (da) 2009-05-04
US20050043357A1 (en) 2005-02-24
AU2004266232A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
CY1108927T1 (el) Αναστολεις μιτωτικης κινεσινης
DE60329756D1 (de) Mitotische kinesin-hemmer
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
DE60329990D1 (de) Mitotische kinesin-hemmer
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
WO2005017190A3 (en) Mitotic kinesin inhibitors
WO2004037171A3 (en) Mitotic kinesin inhibitors
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2005065183A3 (en) Mitotic kinesin inhibitors
NO20070589L (no) Mitotiske kinesin-inhibitorer.
WO2006031348A3 (en) Mitotic kinesin inhibitors
WO2005060654A3 (en) Mitotic kinesin inhibitors
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
WO2006023440A3 (en) Mitotic kinesin inhibitors
WO2004087050A3 (en) Mitotic kinesin inhibitors